Nurix Therapeutics (NRIX) Accumulated Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Accumulated Expenses for 8 consecutive years, with $43.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Accumulated Expenses rose 16.92% year-over-year to $43.3 million; the TTM figure through May 2026 stood at $43.3 million (up 16.92% YoY), while the FY2025 annual figure was $54.9 million, up 44.37% from the prior year.
• Accumulated Expenses declined to $43.3 million in Q2 2026 per NRIX's latest filing, from $60.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $60.0 million in Q1 2026 and bottomed at $11.4 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $30.8 million across 5 years, with a median of $26.4 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 157.02% — and 2023, when it declined 8.33%.
• Nurix Therapeutics' Accumulated Expenses stood at $22.4 million in 2022, then grew by 11.33% to $25.0 million in 2023, then soared by 52.16% to $38.0 million in 2024, then jumped by 44.37% to $54.9 million in 2025, then fell by 21.12% to $43.3 million in 2026.
• Business Quant data shows NRIX's Accumulated Expenses at $43.3 million in Q2 2026, $60.0 million in Q1 2026, and $54.9 million in Q4 2025.